Sulprostone is an analogue of prostaglandin E2 (PGE2) that has oxytocic activity in assays of rat kidney cells and tissues.

In all events, this as well as other potent synthetic EP3 receptor antagonists have the realized or potential ability to promote the beneficial effects of prostaglandin EP3 receptor activation.

[2] Sulprostone (as well as other prostanoids receptor agonists) is in use for inducing medical abortion and ending pregnancy after fetal death,[3] for the treatment of severe atonic postpartum hemorrhage after vaginal delivery,[4] and for removal of the placenta in patients with retained placenta.

[5] Currently, sulprostone along with SC-46275, MB-28767, ONO-AE-248 and other EP3 receptor agonists are in development as drugs for the possible treatment of stomach ulcers in humans.

[6] This drug article relating to the genito-urinary system is a stub.